先声药业预告上半年收入增约27%-29%、经调整利润增约47%-54%

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

## PROFIT ALERT

This announcement is made by Simcere Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “Board”) of directors (“Directors”) of the Company wishes to inform the shareholders of the Company (the “Shareholders”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the “1H 2026”), it is expected that:

- 1) the Group will record a revenue of approximately RMB4,550 million to RMB4,610 million for the 1H 2026, representing an increase of approximately 26.9% to 28.6% as compared to the revenue of approximately RMB3,585 million for the six months ended June 30, 2025 (the “1H 2025”).
- 2) the Group will record a profit attributable to equity shareholders of the Company of approximately RMB810 million to RMB860 million for the 1H 2026, representing an increase of approximately 34.8% to 43.1% as compared to the restated profit attributable to equity shareholders of the Company of approximately RMB601 million for the 1H 2025. The Group will record an adjusted profit attributable to equity shareholders of the Company1 of approximately RMB950 million to RMB1,000 million for the 1H 2026, representing an increase of approximately 46.5% to 54.2% as compared to the restated and adjusted profit attributable to equity shareholders of the Company of approximately RMB649 million for the 1H 2025. The increase in the aforementioned items is primarily attributable to increases in revenue from innovative pharmaceutical business and income from out-licensing.


- 1. To supplement the financial information presented in accordance with Hong Kong Financial Reporting Standards (“HKFRS”), the Group also uses adjusted profit attributable to equity shareholders of the Company as a non-HKFRS measure. Such measure is unaudited in nature and is not required by, or presented in accordance with, HKFRS.
- 2. In October 2025, the Group completed the acquisition of Xianwei (Hainan) Biotechnology Co., Ltd., and the acquisition was deemed as a business combination under common control of the Group in accordance with the Hong Kong Accounting Standards. The Group’s financial information for the 1H 2025 has been restated accordingly to comply with relevant accounting standards.


The adjusted profit attributable to equity shareholders of the Company is defined by the Group as profit attributable to equity shareholders of the Company adjusted for the following items: (i) net realized and unrealized gain/(loss) on financial assets at fair value through profit or loss; (ii) net realized and unrealized gain on associates at fair value through profit or loss; (iii) interest expenses arising from redemption liability; and (iv) income tax effect related to the above items. The Group is of the view that the Group’s management and investors may benefit from referring to such measure in assessing the financial performance of the Group’s core businesses by eliminating the impacts of certain non-recurring, non-cash and/or non-operating items.

The Company is still in the process of finalising the Group’s results for the 1H 2026. The information contained in this announcement is based solely on the preliminary assessment of the Group’s unaudited consolidated management accounts for the 1H 2026, and is subject to finalisation and other potential adjustments, if any, and has not been reviewed or confirmed by the Group’s auditors or the Audit Committee of the Board. Shareholders and potential investors of the Company should refer to the Group’s results announcement for the 1H 2026, which is expected to be published in late August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Hong Kong, July 30, 2026

By order of the Board Simcere Pharmaceutical Group Limited Mr. Ren Jinsheng Chairman and Executive Director

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.